AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms

BCR-ABL negative myeloproliferative neoplasms (MPNs) consist of essential thrombocythemia, polycythemia vera, and myelofibrosis. The majority of patients harbor the JAK2-activating mutation V617F. JAK2 inhibitors were shown to reduce symptom burden and splenomegaly in MPN patients. However, treatmen...

Full description

Bibliographic Details
Main Authors: Antonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, Sarina Paesler, Victoria Gensch, Florian Udonta, Maria Elena Vargas Delgado, Janik Engelmann, Friederike Hoffmann, Philippe Schafhausen, Gunhild von Amsberg, Kristoffer Riecken, Niklas Beumer, Charles D. Imbusch, James Lorens, Thomas Fischer, Klaus Pantel, Carsten Bokemeyer, Isabel Ben-Batalla, Sonja Loges
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000630

Internet

http://journals.lww.com/10.1097/HS9.0000000000000630

Similar Items